| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Metalloporphyrin
|
|---|---|
| References | |
| Additional Infomation |
Background: We evaluated the feasibility of photodynamic diagnosis of bladder cancer by spectrophotometric analysis of excretory urine samples after in vitro treatment with 5-aminolevulinic acid (ALA). Methods: We recruited 61 patients with histologically confirmed bladder cancer following transurethral resection of bladder tumors (TURP) as the bladder cancer group and 50 outpatients without a history of urothelial carcinoma or cancer-related manifestations as the control group. Half of the excretory urine samples were incubated with ALA (ALA-treated group), and the other half were untreated (ALA-untreated group). The absorbance of the samples at an excitation wavelength of 405 nm was measured using a spectrophotometer to detect intracellular protoporphyrin IX levels. The difference in absorbance at 635 nm between the ALA-treated and ALA-untreated groups was calculated. Results: The difference was significantly greater in the bladder cancer group than in the control group (p < 0.001). The difference was also significantly greater in patients with high-grade tumors than in patients with low-grade tumors (p = 0.004), and the difference was also significantly greater in patients with invasive bladder cancer than in patients with non-invasive bladder cancer (p = 0.007). The area under the curve was 0.84. The sensitivity and specificity of the method were 82% and 80%, respectively. Conclusion: We demonstrate that the level of protoporphyrin IX in ALA-treated urinary cells of bladder cancer patients can be quantitatively detected by spectrophotometry. Therefore, this cancer detection system has clinical application potential. [1]
|
| Molecular Formula |
C34H31CLMNN4O4-
|
|---|---|
| Molecular Weight |
650.03
|
| Exact Mass |
650.15
|
| Elemental Analysis |
C, 62.73; H, 4.95; Cl, 5.45; Mn, 8.44; N, 8.61; O, 9.83
|
| CAS # |
120389-54-0
|
| Appearance |
Typically exists as solids at room temperature
|
| LogP |
0
|
| SMILES |
[Cl-][Mn+3]123[N-]4C5C(C)=C(C=C)C4=CC4C(C)=C(C=C)C(=CC6=C(C)C(CCC(=O)[O-])=C(C=C7C(CCC(=O)[O-])=C(C)C(C=5)=N17)[N-]26)N3=4.[H+]
|
| Synonyms |
Manganese(III) Protoporphyrin IX Chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5384 mL | 7.6920 mL | 15.3839 mL | |
| 5 mM | 0.3077 mL | 1.5384 mL | 3.0768 mL | |
| 10 mM | 0.1538 mL | 0.7692 mL | 1.5384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
